capecitabine has been researched along with Hormone-Dependent Neoplasms in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (62.50) | 29.6817 |
| 2010's | 2 (25.00) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Cristofanilli, M; Flaum, L; Gradishar, W; Helenowski, I; Jain, S; Nelson, V; Rademaker, A; Santa-Maria, CA; Shah, AN; Tsarwhas, D | 1 |
| Bellon, J; Brock, J; Come, SE; Golshan, M; Guo, H; Jeong, J; Krop, IE; Morganstern, D; Tolaney, SM; Winer, EP | 1 |
| Guarneri, V | 1 |
| Chen, DR; Chen, ST; Hsieh, CM; Huang, CS; Kuo, SH; Lu, YS; Tseng, LM; Wang, HC; Yeh, DC; Yeh, HT | 1 |
| Kornek, GV; Scheithauer, W; Schüll, B | 1 |
| Dieringer, P; Jonasch, E; Mathew, P; Pagliaro, LC; Rodney, A; Tannir, N | 1 |
| Cavaglione, G; Chamorey, E; Dides, S; Ferrero, JM; Foa, C; Kaphan, R; Lesbats, G; Nouyrigat, P; Oudard, S | 1 |
| Asmar, L; Boehm, KA; Ilegbodu, D; Kolodziej, M; Mull, S; Neubauer, MA; Perrine, G; Pluenneke, RE; Rousey, SR | 1 |
1 review(s) available for capecitabine and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Lapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.
Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Deoxycytidine; Drug Resistance, Neoplasm; ErbB Receptors; Female; Fluorouracil; Humans; Lapatinib; Letrozole; Neoplasms, Hormone-Dependent; Nitriles; Postmenopause; Quinazolines; Receptor, ErbB-2; Trastuzumab; Triazoles | 2009 |
6 trial(s) available for capecitabine and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Phase II study of pembrolizumab and capecitabine for triple negative and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer.
Topics: Adult; Aged; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Drug Resistance, Neoplasm; Estrogen Receptor alpha; Female; Humans; Middle Aged; Neoplasm Metastasis; Neoplasms, Hormone-Dependent; Receptor, ErbB-2; Receptors, Progesterone; Salvage Therapy; Survival Rate; Treatment Outcome; Triple Negative Breast Neoplasms | 2020 |
A phase II study of preoperative capecitabine in women with operable hormone receptor positive breast cancer.
Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Breast Neoplasms; Capecitabine; Chemotherapy, Adjuvant; Deoxycytidine; Female; Fluorouracil; Humans; Middle Aged; Neoplasms, Hormone-Dependent; Preoperative Care; Receptors, Estrogen; Receptors, Progesterone | 2014 |
Phase II study of docetaxel, capecitabine, and cisplatin as neoadjuvant chemotherapy for locally advanced breast cancer.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Capecitabine; Cisplatin; Deoxycytidine; Docetaxel; Female; Fluorouracil; Humans; Middle Aged; Neoadjuvant Therapy; Neoplasms, Hormone-Dependent; Prospective Studies; Taxoids | 2011 |
Phase II study of capecitabine combined with gemcitabine in the treatment of androgen-independent prostate cancer previously treated with taxanes.
Topics: Administration, Oral; Aged; Androgens; Capecitabine; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Fluorouracil; Gemcitabine; Humans; Infusions, Intravenous; Male; Middle Aged; Neoplasm Staging; Neoplasms, Hormone-Dependent; Probability; Prognosis; Prostatic Neoplasms; Salvage Therapy; Survival Analysis; Taxoids; Treatment Outcome | 2006 |
Phase II trial evaluating a docetaxel-capecitabine combination as treatment for hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Capecitabine; Deoxycytidine; Disease Progression; Docetaxel; Dose-Response Relationship, Drug; Fluorouracil; Follow-Up Studies; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Survival Rate; Taxoids; Treatment Outcome | 2006 |
Phase II trial of docetaxel/capecitabine in hormone-refractory prostate cancer.
Topics: Adenocarcinoma; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Capecitabine; Deoxycytidine; Docetaxel; Fluorouracil; Humans; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Survival Rate; Taxoids; Treatment Outcome | 2006 |
1 other study(ies) available for capecitabine and Hormone-Dependent Neoplasms
| Article | Year |
|---|---|
Capecitabine as salvage therapy for a breast cancer patient with extensive liver metastases and associated impairment of liver function.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Breast Neoplasms; Capecitabine; Combined Modality Therapy; Deoxycytidine; Disease-Free Survival; Female; Fluorouracil; Humans; Hyperbilirubinemia; Liver Function Tests; Liver Neoplasms; Lung Neoplasms; Mastectomy; Middle Aged; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Prodrugs; Retreatment; Salvage Therapy | 2003 |